Acebutolol
Acebutolol may decrease the bronchodilatory activities of Levosalbutamol.
Acepromazine
Acepromazine may decrease the vasoconstricting activities of Levosalbutamol.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Levosalbutamol.
Advertisement
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Levosalbutamol.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Levosalbutamol.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Levosalbutamol.
Advertisement
Amoxapine
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Amoxapine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Levosalbutamol.
Apalutamide
The serum concentration of Levosalbutamol can be decreased when it is combined with Apalutamide.
Advertisement
Aripiprazole
Aripiprazole may decrease the vasoconstricting activities of Levosalbutamol.
Asenapine
Asenapine may decrease the vasoconstricting activities of Levosalbutamol.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Levosalbutamol.
Atenolol
Atenolol may decrease the bronchodilatory activities of Levosalbutamol.
Atomoxetine
Atomoxetine may increase the tachycardic activities of Levosalbutamol.
Atorvastatin
The risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atorvastatin.
Atosiban
The risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atosiban.
Azosemide
Levosalbutamol may increase the hypokalemic activities of Azosemide.
Bendroflumethiazide
Levosalbutamol may increase the hypokalemic activities of Bendroflumethiazide.
Benzthiazide
Levosalbutamol may increase the hypokalemic activities of Benzthiazide.
Benzylpenicilloyl polylysine
Levosalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Betahistine.
Betaxolol
Betaxolol may decrease the bronchodilatory activities of Levosalbutamol.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Levosalbutamol.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Levosalbutamol.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Levosalbutamol.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Levosalbutamol.
Brexpiprazole
Brexpiprazole may decrease the vasoconstricting activities of Levosalbutamol.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosalbutamol.
Bumetanide
Levosalbutamol may increase the hypokalemic activities of Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Levosalbutamol.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Levosalbutamol.
Butriptyline
The risk or severity of adverse effects can be increased when Butriptyline is combined with Levosalbutamol.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Levosalbutamol.
Carteolol
Carteolol may decrease the bronchodilatory activities of Levosalbutamol.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Levosalbutamol.
Celiprolol
Celiprolol may decrease the bronchodilatory activities of Levosalbutamol.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Levosalbutamol.
Chlorothiazide
Levosalbutamol may increase the hypokalemic activities of Chlorothiazide.
Chlorpromazine
Chlorpromazine may decrease the vasoconstricting activities of Levosalbutamol.
Chlorthalidone
Levosalbutamol may increase the hypokalemic activities of Chlorthalidone.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Levosalbutamol.
Clozapine
Clozapine may decrease the vasoconstricting activities of Levosalbutamol.
Cyclopenthiazide
Levosalbutamol may increase the hypokalemic activities of Cyclopenthiazide.
Dapiprazole
Dapiprazole may decrease the vasoconstricting activities of Levosalbutamol.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Levosalbutamol.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Levosalbutamol.
Dextroamphetamine
Dextroamphetamine may decrease the vasoconstricting activities of Levosalbutamol.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Levosalbutamol.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Levosalbutamol.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levosalbutamol.
Dothiepin
The risk or severity of adverse effects can be increased when Dosulepin is combined with Levosalbutamol.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Levosalbutamol.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Levosalbutamol.
Dronedarone
Dronedarone may decrease the vasoconstricting activities of Levosalbutamol.
Droperidol
Droperidol may decrease the vasoconstricting activities of Levosalbutamol.
Duloxetine
Duloxetine may increase the tachycardic activities of Levosalbutamol.
Eltrombopag
The serum concentration of Levosalbutamol can be increased when it is combined with Eltrombopag.
Epinephrine
Epinephrine may decrease the vasoconstricting activities of Levosalbutamol.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Levosalbutamol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Levosalbutamol.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Levosalbutamol.
Escitalopram
Escitalopram may decrease the vasoconstricting activities of Levosalbutamol.
Esmolol
Esmolol may decrease the bronchodilatory activities of Levosalbutamol.
Ethacrynate
Levosalbutamol may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Levosalbutamol may increase the hypokalemic activities of Etacrynic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Levosalbutamol.
Flupenthixol
Flupentixol may decrease the vasoconstricting activities of Levosalbutamol.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Levosalbutamol.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Levosalbutamol.
Furosemide
Levosalbutamol may increase the hypokalemic activities of Furosemide.
Hydrochlorothiazide
Levosalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Levosalbutamol may increase the hypokalemic activities of Hydroflumethiazide.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Levosalbutamol.
Iloperidone
Iloperidone may decrease the vasoconstricting activities of Levosalbutamol.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Levosalbutamol.
Indapamide
Levosalbutamol may increase the hypokalemic activities of Indapamide.
Indoramin
Indoramin may decrease the vasoconstricting activities of Levosalbutamol.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Levosalbutamol.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Levosalbutamol.
Labetalol
Labetalol may decrease the vasoconstricting activities of Levosalbutamol.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Levosalbutamol.
Lisdexamfetamine
Lisdexamfetamine may decrease the vasoconstricting activities of Levosalbutamol.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the vasoconstricting activities of Levosalbutamol.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Levosalbutamol.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Levosalbutamol.
Loxapine
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Loxapine.
MELITRACEN
The risk or severity of adverse effects can be increased when Melitracen is combined with Levosalbutamol.
Mepindolol
Mepindolol may decrease the bronchodilatory activities of Levosalbutamol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Levosalbutamol.
Methotrimeprazine
Methotrimeprazine may decrease the vasoconstricting activities of Levosalbutamol.
Methyclothiazide
Levosalbutamol may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Levosalbutamol.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Levosalbutamol.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Levosalbutamol.
Metolazone
Levosalbutamol may increase the hypokalemic activities of Metolazone.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Levosalbutamol.
Milnacipran
Milnacipran may increase the tachycardic activities of Levosalbutamol.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Levosalbutamol.
Moclobemide
The risk or severity of adverse effects can be increased when Moclobemide is combined with Levosalbutamol.
Nadolol
Nadolol may decrease the bronchodilatory activities of Levosalbutamol.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Levosalbutamol.
Nefazodone
Nefazodone may decrease the vasoconstricting activities of Levosalbutamol.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Levosalbutamol.
Nicardipine
Nicardipine may decrease the vasoconstricting activities of Levosalbutamol.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Levosalbutamol.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Levosalbutamol.
Olanzapine
Olanzapine may decrease the vasoconstricting activities of Levosalbutamol.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Levosalbutamol.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Levosalbutamol.
Paliperidone
Paliperidone may decrease the vasoconstricting activities of Levosalbutamol.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Levosalbutamol.
Penbutolol
Penbutolol may decrease the bronchodilatory activities of Levosalbutamol.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Levosalbutamol.
Periciazine
Propericiazine may decrease the vasoconstricting activities of Levosalbutamol.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Levosalbutamol.
Phenoxybenzamine
Phenoxybenzamine may decrease the vasoconstricting activities of Levosalbutamol.
Phentolamine
Phentolamine may decrease the vasoconstricting activities of Levosalbutamol.
Phentolamine Mesylate
Phentolamine may decrease the vasoconstricting activities of Levosalbutamol.
Pindolol
Pindolol may decrease the bronchodilatory activities of Levosalbutamol.
Piretanide
Levosalbutamol may increase the hypokalemic activities of Piretanide.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Levosalbutamol.
Pizotyline
Pizotifen may decrease the vasoconstricting activities of Levosalbutamol.
Polythiazide
Levosalbutamol may increase the hypokalemic activities of Polythiazide.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Levosalbutamol.
Prazosin
Prazosin may decrease the vasoconstricting activities of Levosalbutamol.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Levosalbutamol.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Levosalbutamol.
Promazine
Promazine may decrease the vasoconstricting activities of Levosalbutamol.
Propiomazine
Propiomazine may decrease the vasoconstricting activities of Levosalbutamol.
Propiverine
Propiverine may decrease the vasoconstricting activities of Levosalbutamol.
Propranolol
Propranolol may decrease the bronchodilatory activities of Levosalbutamol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Levosalbutamol.
Quetiapine
Quetiapine may decrease the vasoconstricting activities of Levosalbutamol.
Quetiapine fumarate
Quetiapine may decrease the vasoconstricting activities of Levosalbutamol.
Quinethazone
Levosalbutamol may increase the hypokalemic activities of Quinethazone.
Quinidine
Quinidine may decrease the vasoconstricting activities of Levosalbutamol.
Racepinephrine
Racepinephrine may decrease the vasoconstricting activities of Levosalbutamol.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Levosalbutamol.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Levosalbutamol.
Risperidone
Risperidone may decrease the vasoconstricting activities of Levosalbutamol.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Levosalbutamol.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Levosalbutamol.
Silodosin
Silodosin may decrease the vasoconstricting activities of Levosalbutamol.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Levosalbutamol.
Sotalol
Sotalol may decrease the bronchodilatory activities of Levosalbutamol.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Levosalbutamol.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Levosalbutamol.
Terazosin
Terazosin may decrease the vasoconstricting activities of Levosalbutamol.
Teriflunomide
The serum concentration of Levosalbutamol can be increased when it is combined with Teriflunomide.
Tertatolol
Tertatolol may decrease the bronchodilatory activities of Levosalbutamol.
Thioproperazine
Thioproperazine may decrease the vasoconstricting activities of Levosalbutamol.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Levosalbutamol.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Levosalbutamol.
Timolol
Timolol may decrease the bronchodilatory activities of Levosalbutamol.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Levosalbutamol.
Tolazoline
Tolazoline may decrease the vasoconstricting activities of Levosalbutamol.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Levosalbutamol.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Levosalbutamol.
Torsemide
Levosalbutamol may increase the hypokalemic activities of Torasemide.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levosalbutamol.
Trazodone
Trazodone may decrease the vasoconstricting activities of Levosalbutamol.
Trichlormethiazide
Levosalbutamol may increase the hypokalemic activities of Trichlormethiazide.
Trifluoperazine
Trifluoperazine may decrease the vasoconstricting activities of Levosalbutamol.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Levosalbutamol.
Urapidil
Urapidil may decrease the vasoconstricting activities of Levosalbutamol.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levosalbutamol.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Levosalbutamol.
Verapamil
Verapamil may decrease the vasoconstricting activities of Levosalbutamol.
Ziprasidone
Ziprasidone may decrease the vasoconstricting activities of Levosalbutamol.
Zuclopenthixol
Zuclopenthixol may decrease the vasoconstricting activities of Levosalbutamol.
